Fill out the form to download brochures
System layout brochure
EarlySense All-in-One brochure
EarlySense Safety brochure
EarlySense Vitals brochure
Selected case studies booklet
I would like more information on
First Name*:
Last Name*:
Mailing address:
Mailing address (line 2):
Feb 9, 2018
Percept, the World’s First Contact-Free Fertility Tracker, Now Eligible for FSA Medical Reimbursement


Announcement Aligns with National Benefits Trend – Majority of Employers Now Offer Fertility Benefits to Attract and Retain Top Talent, Millennials


WOBURN, Mass. (February 9, 2018)EarlySense, the market leader in contact-free health monitoring solutions, today announced that the company’s award-winning and clinically-validated Percept fertility tracker, is now eligible as a Flexible Spending Account (FSA) reimbursable expense. Employees with an FSA account can now use their tax-free dollars to purchase Percept, giving more women access to a simple-to-use device that helps them get pregnant more quickly and easily.


Percept is a contact-free device that slips under a mattress, monitors key vital signs such as heart and respiratory rates, and sleep and stress levels, and accurately predicts a woman’s 6-day fertility window. In a recent clinical study, Percept predicted when the user was most fertile with 31% higher accuracy than standard ovulation estimation processes. The information is sent in real-time to a smartphone, empowering women who are trying to get pregnant to conceive faster and plan ahead. Best of all, Percept requires little effort and almost no changes to daily habits.


Percept’s FSA medical reimbursement eligibility comes at a time when an increasing number of employers are offering fertility benefits as a means of attracting and retaining top talent. In a January 2018 study entitled 2017 Maternity, Family and Fertility Survey released by Willis Towers Watson, two-thirds (66%) of employers are expected to offer fertility benefits by 2019, up from 55% in 2017. According to the study, innovative employers view fertility benefits as a means to support diversity initiatives, recruit and retain talent, achieve industry recognition, and align with their corporate strategy or mission.


“Employers are evolving their health care programs to reflect that fertility benefits are becoming more important to many employees…” said Jeff Levin-Scherz, M.D., North American co-leader, health management practice at Willis Towers Watson. “The additional coverage is often a win-win proposition. It allows employers to provide a valued employee benefit while improving their ability to attract and retain top talent and support diversity initiatives.”


“As we continue to develop strategic partnerships with insurers, benefit brokers and consultants, they will be able to provide their customers access to EarlySense technology and products,” said Michael Martocci, Head of Strategic Partnerships and Business Development, North America at EarlySense. “Having Percept approved for FSA reimbursement makes this valuable fertility benefit even more accessible to the consumer.”

EarlySense is backed by the guidance and counsel of the world’s leading physicians, and is the first company to bring clinically-validated and contact-free digital health technology to the women’s fertility tracking market. Percept is listed with the U.S. Food and Drug Administration (FDA) as a device intended to track physiological parameters as an aid to conception. FSA medical reimbursement eligibility now enables even more women to access Percept. Percept retails for $199 and can be purchased directly at



About EarlySense

EarlySense® provides contact-free, continuous monitoring solutions for the medical and consumer digital health markets. EarlySense’s FDA-cleared systems utilize Artificial Intelligence (AI) and big data analytics to provide actionable health insights and improve clinical outcomes.


Used worldwide in hospitals, rehab and skilled nursing facilities, EarlySense assists clinicians in early detection of patient deterioration, helping to prevent adverse events, including code blues which are a result of cardiac or respiratory arrest, preventable ICU transfers, patient falls and pressure ulcers.


EarlySense offers clinically-proven technology to consumers with EarlySense® Live™ and Percept™. EarlySense® Live™ is the first at-home consumer health monitor powered by EarlySense’s medically-proven sensor and AI analytics. Live is particularly useful for tracking the health and sleep of the aging population and children, to help facilitate better health choices. EarlySense® Percept™ is the first clinically-proven contact-free monitor for fertility and period tracking. It accurately tracks internal body signals and assists couples who are trying to conceive.


EarlySense has partnered with leading global technology companies including Samsung, Welch Allyn, iFit and Beurer. The company is based in Ramat Gan, Israel and Woburn, MA.
For more information, visit, and

Follow EarlySense on LinkedInTwitter and Facebook, EarlySense Live on Facebook and Twitter and Percept at Facebook, Instagram, and Twitter.